# Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity

> **NCT00990223** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Eplerenone or Placebo

## Key facts

- **NCT ID:** NCT00990223
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990223, "Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00990223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*